501 related articles for article (PubMed ID: 28401522)
1. Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.
Barrett FS; Griffiths RR
Curr Top Behav Neurosci; 2018; 36():393-430. PubMed ID: 28401522
[TBL] [Abstract][Full Text] [Related]
2. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
Griffiths RR; Johnson MW; Richards WA; Richards BD; Jesse R; MacLean KA; Barrett FS; Cosimano MP; Klinedinst MA
J Psychopharmacol; 2018 Jan; 32(1):49-69. PubMed ID: 29020861
[TBL] [Abstract][Full Text] [Related]
3. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
Barrett FS; Johnson MW; Griffiths RR
J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
[TBL] [Abstract][Full Text] [Related]
4. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
[TBL] [Abstract][Full Text] [Related]
5. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
Griffiths RR; Richards WA; McCann U; Jesse R
Psychopharmacology (Berl); 2006 Aug; 187(3):268-83; discussion 284-92. PubMed ID: 16826400
[TBL] [Abstract][Full Text] [Related]
6. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.
Griffiths R; Richards W; Johnson M; McCann U; Jesse R
J Psychopharmacol; 2008 Aug; 22(6):621-32. PubMed ID: 18593735
[TBL] [Abstract][Full Text] [Related]
7. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
[TBL] [Abstract][Full Text] [Related]
8. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
MacLean KA; Johnson MW; Griffiths RR
J Psychopharmacol; 2011 Nov; 25(11):1453-61. PubMed ID: 21956378
[TBL] [Abstract][Full Text] [Related]
9. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
[TBL] [Abstract][Full Text] [Related]
10. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR
Psychopharmacology (Berl); 2018 Feb; 235(2):521-534. PubMed ID: 29116367
[TBL] [Abstract][Full Text] [Related]
11. Psilocybin occasioned mystical-type experiences.
James E; Robertshaw TL; Hoskins M; Sessa B
Hum Psychopharmacol; 2020 Sep; 35(5):e2742. PubMed ID: 32573835
[TBL] [Abstract][Full Text] [Related]
12. Alterations of consciousness and mystical-type experiences after acute LSD in humans.
Liechti ME; Dolder PC; Schmid Y
Psychopharmacology (Berl); 2017 May; 234(9-10):1499-1510. PubMed ID: 27714429
[TBL] [Abstract][Full Text] [Related]
13. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
Lyvers M; Meester M
J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
[TBL] [Abstract][Full Text] [Related]
14. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu A; Griffiths RR; Johnson MW
Curr Drug Abuse Rev; 2014; 7(3):157-64. PubMed ID: 25563443
[TBL] [Abstract][Full Text] [Related]
15. The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving.
Sweat NW; Bates LW; Hendricks PS
J Psychoactive Drugs; 2016; 48(5):344-350. PubMed ID: 27719438
[TBL] [Abstract][Full Text] [Related]
16. Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial.
Rothberg RL; Azhari N; Haug NA; Dakwar E
J Psychopharmacol; 2021 Feb; 35(2):150-158. PubMed ID: 33307947
[TBL] [Abstract][Full Text] [Related]
17. Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland.
Kangaslampi S; Hausen A; Rauteenmaa T
J Psychoactive Drugs; 2020; 52(4):309-318. PubMed ID: 32511073
[TBL] [Abstract][Full Text] [Related]
18. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
[TBL] [Abstract][Full Text] [Related]
19. Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin.
Maclean KA; Leoutsakos JM; Johnson MW; Griffiths RR
J Sci Study Relig; 2012 Dec; 51(4):721-737. PubMed ID: 23316089
[TBL] [Abstract][Full Text] [Related]
20. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy.
Hendricks PS
Int Rev Psychiatry; 2018 Aug; 30(4):331-342. PubMed ID: 30260256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]